3 August 2018

Contents

Editorial

• 03 August 2018: vol 19 no 13: AIDS 2018 – first reports

Conference reports

• 22nd International AIDS Conference (AIDS 2018) – first reports

• Caution on press conference news from AIDS 2018

• Zero HIV transmissions in PARTNER 2 study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV

• DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study

• Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study  

• Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil 

• WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018)

• No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018)

• Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN-1

• First randomised kick-and-kill cure study fails to reduce HIV reservoir: RIVER study reports vorinostat and vaccines show activity, but not enough

• Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen

• Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians

• AIDS 2018 online: links to selected webcasts

• 10th International Workshop on HIV Paediatrics – first reports

• Preconception safety signal with dolutegravir: data from the Tsepamo study

PDFs

• 03 August 2018: vol 19 no 13